BCG-Impfung
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/3/4/0/4/9/000002_thumb.jpg)
The bacillus Calmette–Guérin (BCG) vaccine is the only vaccine available for Mycobacterium tuberculosis and despite its global use for 90 years, with proven efficacy and a good safety record, has well-known limitations. It provides only limited protection against pulmonary tuberculosis.
The vaccine comprises a live attenuated strain of Mycobacterium bovis, which lacks any intrinsic virulence.
It also has an important role in the immunotherapy of early stage bladder carcinoma .
History and etymology
The Bacillus Calmette–Guérin vaccine was researched for more than ten years by two French bacteriologists before entering clinical use. The scientists were Leon Charles Albert Calmette (1863-1933), in Nice, France, and Camille Guérin (1872-1961), working at the Pasteur Institute .
Initial trials of their vaccine in cattle in 1924 were a success. Tragically in December 1929, a large trial of 251 neonates with the new vaccine at Lubeck General Hospital in Germany, resulted in 72 deaths due to inadvertent contamination of the vaccine with a live virulent strain during manufacture of the inoculum. This has become known as the Lubeck disaster and was unsurprisingly a major international health scandal at the time . Nevertheless, the vaccine was successfully introduced in 1930, initially in France and Norway. Although it was not licensed for regular use in the UK until 1946 .
Siehe auch:
![Click für weniger anzeigen](/sites/all/modules/pacs/tools/imgs/collapse_up.png)
![](/sites/all/modules/pacs/tools/imgs/Iris_color_40.png)